NFE2L2 and breast cancer: Comparisons of the 28 paired primary metastatic breast cancers revealed differential expression patterns of G6PDH (n = 6, 21.4%, p = 0.688), 6PGL (n = 4, 14.3%, p = 1.000), 6PGDH (n = 1, 3.6%, p = 1.000), cytoplasmic NRF2 (n = 3, 10.7%, p = 1.000), and nuclear NRF2 (n = 3, 10.7%, p = 1.000) (Figure 2).